/YDES

YDES Stock - YD Bio Limited Ordinary Shares

Q: What is the analyst price target for YDES?

Analyst price target information is not currently available for YDES.

Q: What is YDES's market cap?

Market capitalization information is not currently available for YDES.

Healthcare|Biotechnology|NASDAQ

$11.82-0.76%

$0.09 (-0.76%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $13.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for YDES

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.11

52W High$25.00

52W Low$5.30

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$510,360	$350,131	N/A	N/A	N/A
Gross Profit	$155,356	$153,445	N/A	N/A	N/A
Gross Margin	30.4%	43.8%	N/A	N/A	N/A
Operating Income	$-1,461,930	$-9,847	$-2,323,153	$-1,722,364	$-344,223
Net Income	$-1,411,559	$13,560	$3.79M	$8.70M	$-2,537,690
Net Margin	-276.6%	3.9%	N/A	N/A	N/A
EPS	$-0.56	$0.00	$0.41	$0.59	$-0.17

Company Overview

Breeze Holdings Acquisition Corp. operates as a clinical-stage biopharmaceutical company focuses on cancer prevention medical diagnostics and the development of exosome-based therapeutics with the potential to transform the treatment of a diseases with unmet medical need. The company is based in Taipei, Taiwan.

Visit Website

Frequently Asked Questions about YDES

What is YDES's current stock price?

YD Bio Limited Ordinary Shares (YDES) is currently trading at $11.82 per share. The stock has moved -0.76% today.

What is the analyst price target for YDES?

No analyst price targets are currently available for this stock.

What sector is YD Bio Limited Ordinary Shares in?

YD Bio Limited Ordinary Shares operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is YDES's market cap?

YD Bio Limited Ordinary Shares has a market capitalization of $0.83 billion, making it a small-cap company.

Does YDES pay dividends?

No, YD Bio Limited Ordinary Shares does not currently pay a dividend to shareholders.